Antiplatelet therapy after percutaneous coronary intervention: current status and future perspectives

被引：31
|
作者：
Natsuaki, Masahiro [1 ]
Sonoda, Shinjo [1 ]
Yoshioka, Goro [1 ]
Hongo, Hiroshi [1 ]
Kaneko, Tetsuya [1 ]
Kashiyama, Kuninobu [1 ]
Yokoi, Kensuke [1 ]
Hikichi, Yutaka [2 ]
Node, Koichi [1 ]
机构：
[1] Saga Univ Hosp, Dept Cardiovasc Med, 5-1-1 Nabeshima, Saga 8498501, Japan
[2] Saga Med Ctr, Cardiovasc Ctr, Koseikan, Saga, Japan
来源：
CARDIOVASCULAR INTERVENTION AND THERAPEUTICS | 2022年 / 37卷 / 02期
关键词：
Antiplatelet therapy; Antithrombotic therapy; Percutaneous coronary intervention; ELUTING STENT IMPLANTATION; ARTERY-DISEASE; CARDIOVASCULAR EVENTS; ATRIAL-FIBRILLATION; OPTIMAL DURATION; VASCULAR EVENTS; FOCUSED UPDATE; DOUBLE-BLIND; CLOPIDOGREL; ASPIRIN;
D O I：
10.1007/s12928-022-00847-1
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Antiplatelet therapy after percutaneous coronary intervention (PCI) has been changing in parallel with the development of drug-eluting stents (DES) and antiplatelet agents. The recommendation of dual antiplatelet therapy duration is getting shorter due to the decreased risk of stent thrombosis in new-generation DES, the use of a P2Y(12) inhibitor as a monotherapy, and the increasing prevalence of high bleeding risk patients. Antithrombotic therapy after PCI has also changed due to the introduction of direct oral anticoagulants. Aspirin-free P2Y(12) inhibitor monotherapy is now being evaluated in several prospective studies as a novel strategy of antiplatelet therapy after PCI. This review shows a current status and provides future perspectives for the antiplatelet therapy after PCI.
引用
收藏
页码：255 / 263
页数：9
相关论文
共 50 条
  • [41] Single antiplatelet therapy with use of prasugrel in patients undergoing percutaneous coronary intervention
    Otsuka, Tatsuhiko
    Ueki, Yasushi
    Kavaliauskaite, Raminta
    Zanchin, Thomas
    Bar, Sarah
    Stortecky, Stefan
    Pilgrim, Thomas
    Valgimigli, Marco
    Meier, Bernhard
    Heg, Dik
    Windecker, Stephan
    Raber, Lorenz
    CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2021, 98 (02) : E213 - E221
  • [42] The Evolution of Antiplatelet Therapy After Percutaneous Coronary Interventions: A 40-Year Journey
    Marquis-Gravel, Guillaume
    Robert-Halabi, Maxime
    Bainey, Kevin R.
    Tanguay, Jean-Francois
    Mehta, Shamir R.
    CANADIAN JOURNAL OF CARDIOLOGY, 2022, 38 (10) : S79 - S88
  • [43] Current status and prospects of antiplatelet therapy in percutaneous coronary intervention in Japan: Focus on adenosine diphosphate receptor inhibitors
    Ogawa, Hisao
    Hokimoto, Seiji
    Kaikita, Koichi
    Yamamoto, Koichiro
    Chitose, Tadasuke
    Ono, Takamichi
    Tsujita, Kenichi
    JOURNAL OF CARDIOLOGY, 2011, 58 (01) : 6 - 17
  • [44] Is It Really Safe to Discontinue Antiplatelet Therapy 12 Months After Percutaneous Coronary Intervention in Patients with Atrial Fibrillation?
    Abdulrahman, Balen
    Jabbour, Richard J.
    Curzen, Nick
    INTERVENTIONAL CARDIOLOGY-REVIEWS RESEARCH RESOURCES, 2023, 18
  • [45] Antithrombotic therapy after percutaneous coronary intervention from the Japanese perspective
    Saito, Yuichi
    Kobayashi, Yoshio
    Tanabe, Kengo
    Ikari, Yuji
    CARDIOVASCULAR INTERVENTION AND THERAPEUTICS, 2020, 35 (01) : 19 - 29
  • [46] Current status of antithrombotic therapy and in-hospital outcomes in patients with atrial fibrillation undergoing percutaneous coronary intervention in Germany
    Zeymer, Uwe
    Toelg, Ralph
    Wienbergen, Harm
    Hobbach, Hans-Peter
    Cuneo, Alessandro
    Bekeredjian, Raffi
    Ritter, Oliver
    Hailer, Birgit
    Hertting, Klaus
    Hennersdorf, Marcus
    Scholtz, Werner
    Lanzer, Peter
    Mudra, Harald
    Schwefer, Markus
    Schwimmbeck, Peter-Lothar
    Liebetrau, Christoph
    Thiele, Holger
    Claas, Christoph
    Riemer, Thomas
    Zahn, Ralf
    HERZ, 2023, 48 (02) : 134 - 140
  • [47] Update on Antithrombotic Therapy after Percutaneous Coronary Intervention
    Saito, Yuichi
    Kobayashi, Yoshio
    INTERNAL MEDICINE, 2020, 59 (03) : 311 - 321
  • [48] Controversies of oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention
    Rajagopal, V
    Bhatt, DL
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2004, 30 (06) : 649 - 655
  • [49] Case-fatality rate of major bleeding events in patients on dual antiplatelet therapy after percutaneous coronary intervention: A systematic review and meta-analysis
    Tritschler, Tobias
    Patel, Anuj
    Kraaijpoel, Noemie
    Bhatt, Deepak L.
    De Luca, Giuseppe
    Di Santo, Pietro
    Feres, Fausto
    Costa, Ricardo A.
    Hibbert, Benjamin
    Isshiki, Takaaki
    Le Gal, Gregoire
    Castellucci, Lana A.
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2022, 6 (07)
  • [50] Sex-Based Outcomes of Dual-Antiplatelet Therapy After Percutaneous Coronary Intervention: A Pairwise and Network Meta-Analysis
    Agbaedeng, Thomas A.
    Noubiap, Jean Jacques
    Roberts, Kirsty A.
    Chew, Derek P.
    Psaltis, Peter J.
    Amare, Azmeraw T.
    DRUGS, 2024, : 685 - 701
12345